JP2014505264A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505264A5
JP2014505264A5 JP2013553610A JP2013553610A JP2014505264A5 JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5 JP 2013553610 A JP2013553610 A JP 2013553610A JP 2013553610 A JP2013553610 A JP 2013553610A JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5
Authority
JP
Japan
Prior art keywords
marker
level
determining
biological sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013553610A
Other languages
English (en)
Japanese (ja)
Other versions
JP5990542B2 (ja
JP2014505264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024729 external-priority patent/WO2012109592A1/en
Publication of JP2014505264A publication Critical patent/JP2014505264A/ja
Publication of JP2014505264A5 publication Critical patent/JP2014505264A5/ja
Application granted granted Critical
Publication of JP5990542B2 publication Critical patent/JP5990542B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013553610A 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法 Expired - Fee Related JP5990542B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161441785P 2011-02-11 2011-02-11
US61/441,785 2011-02-11
US201161442454P 2011-02-14 2011-02-14
US61/442,454 2011-02-14
US201161472424P 2011-04-06 2011-04-06
US61/472,424 2011-04-06
PCT/US2012/024729 WO2012109592A1 (en) 2011-02-11 2012-02-10 Methods for diagnosing systemic lupus erythematosus

Publications (3)

Publication Number Publication Date
JP2014505264A JP2014505264A (ja) 2014-02-27
JP2014505264A5 true JP2014505264A5 (enExample) 2015-04-02
JP5990542B2 JP5990542B2 (ja) 2016-09-14

Family

ID=45774332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553610A Expired - Fee Related JP5990542B2 (ja) 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法

Country Status (4)

Country Link
US (7) US10132813B2 (enExample)
EP (1) EP2673644B1 (enExample)
JP (1) JP5990542B2 (enExample)
WO (1) WO2012109592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
US9863946B2 (en) 2013-02-08 2018-01-09 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
BR112015018964B1 (pt) * 2013-02-08 2022-08-02 Allegheny-Singer Research Institute Método para determinar se um paciente se classifica como não apresentando ter lupus e sistema para executar o método para determinar se um paciente se classifica como não apresentando ter lupus
CN105229470B (zh) * 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
US20170074876A1 (en) * 2014-03-13 2017-03-16 INSERM (Institut National de la Sante et da la Recherche Medicale) Diagnosis Method for Lupus
BR112017002575B1 (pt) * 2014-08-08 2023-11-07 Allegheny Singer Research Institute Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo
WO2016205723A2 (en) * 2015-06-19 2016-12-22 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
WO2017023781A1 (en) * 2015-07-31 2017-02-09 Allegheny-Singer Research Institute Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
KR102608933B1 (ko) * 2021-10-20 2023-12-01 재단법인 아산사회복지재단 전신 홍반성 루푸스 환자의 루푸스 신염 진단용 바이오마커 조성물 및 이를 이용한 루푸스 신염 진단에 필요한 정보를 제공하는 방법
CN119889651B (zh) * 2024-12-24 2025-11-18 北京医院 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256708B2 (en) 1999-06-23 2007-08-14 Visicu, Inc. Telecommunications network for remote patient monitoring
EP1432731B1 (en) 2001-09-10 2010-09-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Diagnosis and monitoring of systemic lupus erythematosus and of scleroderma
CA2522261A1 (en) 2003-04-16 2004-11-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification and monitoring of systematic lupus erythematosus
AU2004249155B2 (en) 2003-06-13 2009-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monitoring immunologic, hematologic and inflammatory diseases
EP2216650A1 (en) 2004-04-09 2010-08-11 University of Pittsburgh Real time method of detecting acute inflammatory conditions
DE602005023725D1 (de) * 2004-05-11 2010-11-04 Univ Pittsburgh Diagnose und überwachung von entzündlichen krankheiten mittels messung der zusätzlichen komponenten von leukozyten
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
CA2648567A1 (en) 2006-04-07 2007-10-18 Academisch Ziekenhuis H.O.D.N. Lumc Systems and methods for predicting an individual's risk of developing rheumatoid arthritus
EP2347259A4 (en) * 2008-10-16 2012-02-29 Cypress Bioscience Inc METHOD FOR DIAGNOSIS AND MONITORING OF ILLICIT ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATODES (SLE) AND OTHER AUTOIMMUNE DISEASES
US20110177531A1 (en) * 2009-10-16 2011-07-21 Exagen Diagnostics, Inc. Cell-Based Complement Activation Product Algorithm for Diagnosing Systemic Lupus Erythematosus
EP2336769A1 (en) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
EP2362222B1 (en) 2010-02-22 2013-06-26 Medipan GmbH Method and device for the simultaneous detection of antibodies bound to synthetic and cellular and/or tissue substrates
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
JP2015511012A (ja) 2012-03-06 2015-04-13 ライフ テクノロジーズ コーポレーション 全身性エリテマトーデスのためのバイオマーカー
CN105229470B (zh) 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法

Similar Documents

Publication Publication Date Title
JP2014505264A5 (enExample)
Mandaliya et al. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
Salumets et al. Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood
Bizzaro et al. Are we at a stage to predict autoimmune rheumatic diseases?
Jansen et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities
Demoruelle et al. Performance of anti–cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease
Didier et al. Immune correlates of aging in outdoor-housed captive rhesus macaques (Macaca mulatta)
US20140315742A1 (en) Biodosimetry panels and methods
Walzl et al. Biomarkers for TB treatment response: challenges and future strategies
Grauer et al. Neurocognitive decline in HIV patients is associated with ongoing T‐cell activation in the cerebrospinal fluid
High et al. Translational research in immune senescence: assessing the relevance of current models
Vos et al. The 2000HIV study: Design, multi-omics methods and participant characteristics
Paczesny Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’biomarker
Lanzillo et al. JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level
CN119534864B (zh) 一种新型的IgG4相关性疾病的标志物及其应用
Zingaropoli et al. JC virus‐DNA detection is associated with CD8 effector accumulation in peripheral blood of patients with multiple sclerosis under natalizumab treatment, independently from JC virus serostatus
JP2017528734A5 (enExample)
Drabe et al. Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo: SOT study): a prospective non-interventional observational trial
Punukollu et al. Genomic and biomarker innovations in predicting kidney transplant rejection
CN119889651B (zh) 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法
Barnes et al. Use of blood based biomarkers in the evaluation of Crohn’s disease and ulcerative colitis
Manzano-Román et al. Protein arrays as tool for studies at the host–pathogen interface
RU2017107273A (ru) Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров
Florez et al. Progress and challenges in diagnosis and treatment of rejection following liver transplantation
CN119626506A (zh) 一种系统性红斑狼疮活动性评估模型的构建方法及其应用